CAAP Company: CellAegis' autoRIC® Device Clinically Implemented in Peel-Halton Region

OBIO News
Written By Guest User

CellAegis autoRIC® Device, which reduces heart damage in ischemic heart disease, is now being clinically implemented in Peel-Halton Region, West of Toronto. The autoRIC® Device is being used to treat all patients having heart attacks, in addition to standard treatment. The FIRST study (Field Implementation of autoRIC® Device in STEMI (ST-segment Myocardial Infarction)) is the first clinical implementation of our device across an entire region, and is expected to be the first of many such clinical implementations, as the benefit of Remote Ischemic Conditioning therapy becomes more widely utilized.

For the full press release click here

Guest User
Previous

CAAP Company: AbCelex awarded $3.4 million government investment to develop new line of anti-microbial feed additives to help control disease outbreaks in poultry flocks
Next

CAAP Company: KA Imaging Receives $1M to develop low-cost lung screening